New medication more potent, longer lasting than morphine

January 4, 2011

(PhysOrg.com) -- A little-known morphinelike drug is potentially more potent, longer lasting and less likely to cause constipation than standard morphine, a study led by a Loyola University Health System anesthesiologist has found.

The drug, morphine-6-0-sulfate, has a similar to standard . Dr. Joseph Holtman Jr. and colleagues reported that a study they performed in rats "demonstrated potential clinical advantages of morphine-6-0-sulfate compared to morphine."

Holtman is first author of the study, published in the December 2010 issue of the European Journal of Pharmacology.

Holtman is medical director of Loyola's Specialty Service and a professor in the departments of Anesthesiology and and Therapeutics of Loyola University Chicago Stritch School of Medicine. He directed the study while he was at the University of Kentucky’s College of Medicine. He joined Loyola on March 1, 2010.

Opioids, such as morphine, oxycodone and hydrocodone, are standard drugs for treating moderate to severe pain, including cancer pain. But these drugs can have significant side effects, including constipation, nausea, vomiting, drowsiness, cognitive dysfunction and slowed breathing and heart rates. And while opioids work well for conditions such as back pain and post-operative pain, the drugs are less effective against neuropathic pain, such as tingling, burning or shooting pain.

Constipation is a common side effect of morphine and can be so uncomfortable that some patients limit their use of the drug. Doctors typically do not discharge surgery patients until they have had a bowel movement and this can extend hospital stays.

Holtman and colleagues tested standard morphine and morphine-6-0-sulfate on rats. The animals received the drugs three ways -- by mouth, by IV and by injection into the space surrounding the spinal cord.

The rats underwent several well-established tests to determine their sensitivity to pain. In one such test, researchers focused a very warm light beam on the tail and measured how long it took for the rat to flick the tail.

In this tail-flick test, morphine-6-0-sulfate was 10 times more potent than standard morphine when administered in the space surrounding the spinal cord, five times more potent when administered by IV and two times more potent when given by mouth. Morphine-6-0-sulfate maintained its maximum effect for three hours, compared with 1½ hours for standard morphine. And it took rats 25 days to build tolerance to morphine-6-0-sulfate, compared with 10 days with standard morphine.

Morphine-6-0-sulfate also was more potent than standard morphine for neuropathic and inflammatory pain.

Researchers found that morphine-6-0-sulfate could cause constipation, but only at doses 10 to 20 times higher than the effective doses.

The findings suggest that morphine-6-0-sulfate "may be an interesting potential drug for further study," Holtman and colleagues wrote.

Related Stories

Recommended for you

Researchers identify drug that alleviates opioid withdrawal

January 30, 2017

Opioid use and abuse is a significant social, health and economic issue in Canada. Researchers at the University of Calgary's Faculty of Veterinary Medicine (UCVM) and Hotchkiss Brain Institute (HBI) have discovered that ...

Detecting counterfeit medicines

January 27, 2017

Bernard Naughton and Dr David Brindley from Oxford University's Saïd Business School and Medical Sciences Division discuss the problems of identifying fake, substandard and expired medicines.

4 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Quantum_Conundrum
2.3 / 5 (3) Jan 04, 2011
...and of course, they'll just charge 10 to 20 times more to administer this drug.
kshultz222_yahoo_com
5 / 5 (1) Jan 04, 2011
The biggest problem is that it will take 10 - 20 years to get it on the market.
ormondotvos
5 / 5 (1) Jan 04, 2011
Well, how hard is it to synthesize?

Big market to constipated chronic pain sufferers ... sell it on the street outside medical cannabis clinics.
wileruilaer
not rated yet Jan 05, 2011
I wonder if addictiveness is also 2-10 times higher. If so, this drug would probably not be very useful for the majority of pain sufferers, but would mostly be used the same way we use the more potent opioids today, in specialized surgical, oncological, neurological and palliative settings where addiction is already considered a secondary problem. In those cases, reduced side effects would be welcome. If, however, this drug also exhibits significantly less addictiveness - this might be a very welcome addition in the arsenal of primary health care pain relief.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.